Madridge Journal of Cancer Study & Research

ISSN: 2640-5180

5th International Conference on Oncology & Virology
July 25-26, 2019 | Holiday Inn Rome Aurelia, Rome, Italy

Ciclopirox Inhibits Hepatitis B Virus Secretion by Blocking Capsid Assembly

Yoon Jun Kim3*, Jung-Ah Kang1, Songwon Kim1, Minji Park2, Hyun-Jin Park1, Jeong-Hyun Kim1, Sanghyeok Park1, Jeong-Ryul Hwang1, Yong-Chul Kim1, Yuri Cho2, Mi Sun Jin1 and Sung-Gyoo Park1

1School of Life Sciences, Gwangju Institute of Science and Technology, Republic of Korea
2Department of Internal Medicine, CHA Gangnam Medical Center, CHA University School of Medicine, Republic of Korea
3Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Republic of Korea

DOI: 10.18689/2640-5180.a4.009

Download PDF

Chronic hepatitis B virus (HBV) infection can cause cirrhosis and hepatocellular carcinoma and is therefore a serious public health problem. Infected patients are currently treated with nucleoside/nucleotide analogs and interferon α, but this approach is not curative. Here, we screen 978 FDA-approved compounds for their ability to inhibit HBV replication in HBV-expressing HepG2.2.15 cells. We find that ciclopirox, a synthetic antifungal agent, strongly inhibits HBV replication in cells and in mice by blocking HBV capsid assembly. The crystal structure of the HBV core protein and ciclopirox complex reveals a unique binding mode at dimer-dimer interfaces. Ciclopirox synergizes with nucleoside/nucleotide analogs to prevent HBV replication in cells and in a humanized liver mouse model. Therefore, orally-administered ciclopirox may provide a novel opportunity to combat chronic HBV infection by blocking HBV capsid assembly.

Dr. Yoon-Jun Kim MD, PhD has been Professor of Internal Medicine at Seoul National University College of Medicine since 2013. While doing so, he remains active in the medical community through taking on leading roles in various professional societies such as Chair of the Academic Committee of The Korean Radio-Embolization Association, a position he has held since 2013, and from 2013 to 2014, he functioned as Chair of Academic Committee of The Korean Liver Cancer Study Group. Also, he served as secretary general of The Korean Liver Cancer Study Group from 2014 to 2015. Concurrently, he has been Editor-in-Chief of Clinical and Molecular Hepatology, a medical journal that publishes clinical and basic research on liver diseases, since 2015. His educational background began in the same college that he is now professor at, where he graduated from Seoul National University College of Medicine in 1992 and later went on to attain his Ph.D. there in 2001. Since graduating, his research interests in his particular field have included clinical studies of HBV infection and HCC, host genomics in HBV-related liver disease, clinical studies of NASH, cancer genomics of HCC, and basic studies of HCC pathogenesis.